Adalta Ltd has released a press release.
Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- Investor briefing-AD-214 top line single dose safety results
- Appendix 4D and Interim Financial Report
- FDA Orphan Drug Designation for AD-214
- Phase I HV extension to explore encouraging results
- AGM Presentation
Later from AdAlta
- AdAlta granted Japanese patent for AD-214
- GE Healthcare collaboration advances to next stage
- R&D Tax Incentive Facility
- AdAlta secures AD-214 resupply
- AD-214 pathway to IPF efficacy studies
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta